The Cystatin B Titration Hypothesis: Cytoplasmic Cathepsin Bias as the Primary Driver of Age-Associated Lysosomal Collapse

I propose that the neurodegenerative "slow burn" isn't just a byproduct of mechanical Lysosomal Membrane Permeabilization (LMP). Instead, it’s a failure of stoichiometry: the Cystatin B (CstB) titration threshold. As neurons age, the cytoplasmic concentration of CstB—the cell’s endogenous inhibitor of cysteine cathepsins—drops below a critical point. This effectively disarms the cell’s primary cytosolic defense against escaped proteases. The result is a positive feedback loop: minor, transient leakage of cathepsins B, L, and S sparks local mitochondrial damage and ROS production. That damage, in turn, drives further lysosomal lipid peroxidation, culminating in systemic, terminal LMP.

While current literature correctly identifies cathepsin D translocation as a trigger for apoptosis cathepsin D translocation, focusing solely on aspartyl proteases overlooks the high-velocity damage caused by cysteine cathepsins. I suspect the initial trigger is actually a slow, chronic leakage of cysteine cathepsins that would normally be checked by cytoplasmic CstB.

1. Stoichiometric Imbalance: In young, healthy neurons, CstB acts as an emergency buffer. If a pore forms, CstB binds the escaped enzyme instantly, neutralizing it before it can degrade cytosolic substrates.
2. The Decline: As CstB levels fade—a gap recently highlighted in existing research cystatin B gap—the cytosolic buffering capacity simply vanishes.
3. Catalytic Amplification: Without CstB, these escaped cathepsins begin cleaving lysosomal and mitochondrial structural proteins. This accelerates the ROS-driven feed-forward loop observed in earlier studies cathepsin D knockdown.

Ultimately, the cell isn't dying because the lysosome leaks; it’s dying because it has lost the ability to neutralize that leakage.

Testing the Hypothesis

This can be tested through two experimental paths:

• CstB-Rescue Assays: In CstB-deficient aged neuronal models, using viral-mediated overexpression of CstB should revert the phenotype from apoptotic or pro-inflammatory back to a stable state, even if amyloid-β aggregates are present. If this rescue halts NLRP3 inflammasome activation cathepsin B-NLRP3, it proves the inhibitor-enzyme ratio is the real mechanistic control point.
• Single-Molecule Tracking: We can use FRET-based probes to track the ratio of active CstB to cathepsin B in aging primary neuron cultures. If cytosolic proteolytic activity spikes precisely when CstB drops—and importantly, if this happens before the loss of mitochondrial membrane potential—then the "Cystatin B Titration Threshold" is the primary kinetic switch of neuronal senescence.

Broader Implications

If this holds up, we should shift therapeutic focus away from blunt, non-specific cathepsin inhibition, which risks stalling lysosomal clearance. Instead, we should look toward Cystatin B mimetic therapy. Restoring the cytoplasmic "protease-buffer" could prevent the transition from a leaky lysosome to a dead cell, fundamentally changing how we approach age-related proteostasis collapse.